Distinguished in Pancreatic Cancer

Dr. Lauren E. Henke

Radiation Oncology
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Pancreatic Cancer
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lauren Henke is a Radiation Oncologist in Cleveland, Ohio. Dr. Henke is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Anal Cancer, Familial Pancreatic Cancer, and Thyroidectomy. Dr. Henke is currently accepting new patients.

Her clinical research consists of co-authoring 90 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 12 articles and participated in 2 clinical trials in the study of Pancreatic Cancer.

Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Uh Cleveland Medical Center
University Hospitals Portage Medical Center
University Hospitals Ahuja Medical Center
Parma Community General Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Recruiting
Publish Date: May 02, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Device, Biological, Radiation
Study Drugs: Paclitaxel, Carboplatin AUC, Durvalumab
Study Phase: Phase 2
Non-Operative Management and Early Response Assessment in Rectal Cancer
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Drug, Radiation
Study Phase: Not Applicable
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
Enrollment Status: Terminated
Publish Date: September 29, 2025
Intervention Type: Radiation, Device
Study Phase: Not Applicable
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Carboplatin, Paclitaxel
Study Phase: Phase 1
Pilot Study of Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy (MAP-RT)
Pilot Study of Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy (MAP-RT)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Device, Radiation
Study Phase: Not Applicable
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Pre-operative Adaptive Short Course Radiation Therapy in Gastric Cancer
Enrollment Status: Terminated
Publish Date: January 09, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Prospective Imaging Study of Target Definition and Simulation-free Planning Workflows on the Halcyon 4.0 System for Patients Receiving Radiation Therapy
A Prospective Imaging Study of Target Definition and Simulation-free Planning Workflows on the Halcyon 4.0 System for Patients Receiving Radiation Therapy
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Device
Study Phase: Not Applicable
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Radiation, Device
Study Phase: Not Applicable
Pilot Study of a Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies
Pilot Study of a Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies
Enrollment Status: Completed
Publish Date: April 18, 2023
Intervention Type: Radiation, Device
Study Phase: Not Applicable
A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
Enrollment Status: Terminated
Publish Date: February 14, 2023
Intervention Type: Device
Study Phase: Not Applicable
Feasibility and Safety of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Feasibility and Safety of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Cone Beam Computed Tomography-Guided On-Table Adaptive Planning in a Novel Ring Gantry Radiotherapy Device
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study of Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
A Pilot Study of Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Pilot Study Evaluating the Safety and Feasibility of MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the Treatment of Locally Advanced Cervical Cancer
A Pilot Study Evaluating the Safety and Feasibility of MR-Guided High-Intensity Focused Ultrasound in Conjunction With Radiation Therapy for the Treatment of Locally Advanced Cervical Cancer
Enrollment Status: Withdrawn
Publish Date: April 01, 2022
Intervention Type: Device, Radiation
Study Phase: Not Applicable
Pilot Study of MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Pilot Study of MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 17, 2019
Intervention Type: Behavioral, Device
Study Phase: Phase 1
View 16 Less Clinical Trials

90 Total Publications

Predicting Tumor Regrowth in Patients Undergoing Non-Operative Management after Total Neoadjuvant Therapy.
Predicting Tumor Regrowth in Patients Undergoing Non-Operative Management after Total Neoadjuvant Therapy.
Journal: Journal of gastrointestinal cancer
Published: October 25, 2025
Similar Doctors
Suzanne M. Russo
Distinguished in Pancreatic Cancer
Dr. Suzanne M. Russo
Radiation Oncology
Distinguished in Pancreatic Cancer
Dr. Suzanne M. Russo
Radiation Oncology

The Metrohealth System

2500 Metrohealth Dr, 
Cleveland, OH 
 (5.7 miles away)
216-778-7800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Suzanne Russo is a Radiation Oncologist in Cleveland, Ohio. Dr. Russo is rated as an Advanced provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Pancreatic Cancer, Breast Cancer, Pleuropulmonary Blastoma, Familial Pancreatic Cancer, and Liver Embolization. Dr. Russo is currently accepting new patients.

Shalini Moningi
Distinguished in Pancreatic Cancer
Dr. Shalini Moningi
Radiation Oncology
Distinguished in Pancreatic Cancer
Dr. Shalini Moningi
Radiation Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shalini Moningi is a Radiation Oncologist in Cleveland, Ohio. Dr. Moningi has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Pancreatic Cancer, Prostate Cancer, Familial Prostate Cancer, Pancreaticoduodenectomy, and Prostatectomy.

Distinguished in Pancreatic Cancer
Dr. Jennifer A. Dorth
Radiation Oncology
Distinguished in Pancreatic Cancer
Dr. Jennifer A. Dorth
Radiation Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Dorth is a Radiation Oncologist in Cleveland, Ohio. Dr. Dorth is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Anal Cancer, Pancreatic Cancer, Prostate Cancer, Laryngeal Cancer, and Tissue Biopsy. Dr. Dorth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Henke's expertise for a condition
ConditionClose
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile